Ligand Pharmaceuticals Incorporated (LGND)
After hours:
| Previous Close | 84.91 |
| Open | 85.60 |
| Bid | 86.12 x 200 |
| Ask | 86.75 x 100 |
| Day's Range | 84.68 - 86.65 |
| 52 Week Range | 49.24 - 94.57 |
| Volume | |
| Avg. Volume | 189,666 |
| Market Cap | 1.552B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | 16.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 02, 2010 |
| 1y Target Est | N/A |
- Business Wire
Ligand to Participate in Upcoming Investor Conferences
JUPITER, Fla., May 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences:
- Business Wire
Ligand Reports First Quarter 2024 Financial Results
JUPITER, Fla., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions.
- Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
JUPITER, Fla. and LEXINGTON, Mass., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with met
